Intervention for Diabetes with Education, Advancement and Support (IDEAS) study: Protocol for a cluster randomised controlled trial by Lee, Jun Y. et al.
STUDY PROTOCOL Open Access
Intervention for Diabetes with Education,
Advancement and Support (IDEAS) study:
protocol for a cluster randomised
controlled trial
Jun Yang Lee1, Carina Ka Yee Chan2,3, Siew Siang Chua4, Chirk Jenn Ng5, Thomas Paraidathathu5,
Kenneth Kwing-Chin Lee1 and Shaun Wen Huey Lee1*
Abstract
Background: The high market penetration of mobile phones has triggered an opportunity to combine mobile
technology with health care to overcome challenges in today’s health care setting. Although Malaysia has a high
Internet and mobile penetration rate, evaluations of the efficacy of incorporating this technology in diabetes care is
not common. We report the development of a telemonitoring coaching system, using the United Kingdom (UK)
Medical Research Council (MRC) framework, for patients with type 2 diabetes mellitus.
Methods: The Intervention for Diabetes with Education, Technological Advancement and Support (IDEAS) study is
a telemonitoring programme based on an empowerment philosophy to enable participants to be responsible for
their own health decision and behaviour. An iterative cycle of development, piloting, and collating qualitative and
quantitative data will be used to inform and refine the intervention. To increase compliance, the intervention will
be designed to encourage self-management using simple, non-technical knowledge. The primary outcomes will be
HbA1c, blood pressure, total cholesterol, and quality of life and diabetes self-efficacy. In addition, an economic
analysis on health service utilisation will be collected.
Discussion: The mixed-method approach in this study will allow for a holistic overview of using telemonitoring in
diabetes care. This design enables researchers to understand the effectiveness of telemonitoring as well as provide
insights towards the receptiveness of incorporating information technology amongst type 2 diabetes patients in a
community setting.
Trial registration: ClinicalTrials.gov NCT02466880 Registered 2 June 2015.
Keywords: Diabetes management, Remote monitoring, Telemonitoring, Type 2 diabetes mellitus
Background
Globally, an estimated 385 million people are living with
diabetes, and this is expected to increase to 552 million
by 2030 [1, 2] . This increasing prevalence of diabetes,
especially type 2, poses a major public health concern, as
it is associated with substantial morbidity, mortality, as
well as financial cost due to the associated microvascular
and macrovascular complications. In Malaysia, type 2
diabetes affects approximately 12 % of the total popula-
tion and, together with ischaemic heart disease, consti-
tute nearly 75 % of the total non-communicable disease
burden [3]. Clinical care of diabetes currently consumes
approximately 16 % of the total national healthcare
budget in Malaysia, with an estimated RM2.4 billion
(about USD0.55 billion) spent in 2010 [4]. A recent
study in Malaysia reported that patients with diabetes
spent up to 14.7 % of their household income on
outpatient diabetes care [5].
The utilization of self-monitoring blood glucose
(SMBG) for individuals with diabetes is low, with only
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6.9 and 26.8 % of people with diabetes utilising SMBG in
private and public hospitals, respectively [6]. The utilisa-
tion of SMBG in people with diabetes is complex.
Financial, psychological, and behavioural factors can
affect an individual’s utilisation of SMBG [6–8].
Innovative methods are required to overcome these
challenges. Currently, with the advancement of tech-
nology, there is a promising potential to overcome
such barriers [9, 10].
Remote patient monitoring or telemonitoring has re-
cently gained much attention as a promising and innova-
tive solution to improve patient care and management
from a distance, especially for those with diabetes. It
involves the use of telecommunication technologies such
as video, audio, handheld technologies or intelligent
sensors for the digital transmission of physiological and
other disease related data for monitoring patient’s condi-
tion and clinician’s feedback [11, 12]. Systematic reviews
of telemonitoring intervention in diabetes, asthma, heart
failure and hypertension showed that telemonitoring is a
safe, effective and acceptable intervention method with
better glycaemic control, significant improvements in
peak respiratory flows and reduction in systolic or dia-
stolic blood pressure [13, 14]. Additionally, due to the
algorithmic structure of computerised systems, data
reported by patients were entirely accurate, overcoming
the challenges of inaccurate results [15–17].
However, there is limited evidence regarding the feasi-
bility of translating telemonitoring research into practice
in a developing country such as Malaysia. Malaysia with
a population of 29 million people has a mobile penetra-
tion rate of 140 %, indicating that 47 % of Malaysians
own more than one mobile phone [18, 19]. Furthermore,
Malaysia has a total of 20 million Internet users and 15
million people are subscribers of third generation (3G)
networks, indicating a potential to incorporate mobile
telemonitoring among the general public [18, 19]. There-
fore, this study will design a system, which incorporates
current technology, and evaluate the practicality of such
a system in patient care, for people diagnosed with type
2 diabetes in Malaysia. The focus of the study will be on
the use of remote monitoring to maximise the use of
information and communications technology (ICT) to
deliver lifestyle intervention, provide accurate data, as
well as influence patients’ attitude and behaviour in a
community setting in Malaysia. This study will include
various factors working interdependently with each
other, including an automated feedback mechanism for
diabetes monitoring, cost effectiveness, diabetes educa-
tion as well as a focus group to understand participants
point of view for future intervention implementation.
The UK Medical Research Council (MRC) framework
for complex intervention will be used to guide the devel-
opment and evaluation of this current study.
This framework emphasises that the development,
evaluation and implementation of any complex interven-
tion require a strong theoretical foundation [20, 21].
Furthermore, a wide spectrum of intervention studies
which required behavioural changes, information
services, education programmes, integrated systems of
patient care and complementary therapies have been
conducted using this approach [21, 22]. The MRC
framework suggests a progression of different phases,
starting from the pre-clinical phase up to phase IV
clinical trials (Fig. 1). This article will discuss how the
MRC framework criteria are used to develop the current
study.
Methods/design
Aim of the study
The aim of this cluster randomised controlled study is
to evaluate the effectiveness of the Intervention for
Diabetes with Education, Technological Advancement
and Support (IDEAS) among type 2 diabetes adults, in
reducing serum HbA1c levels. The IDEAS involves data
transmission, feedback and education.
Outcome measures
The primary outcome of this study is changes in HbA1c
levels pre and post intervention. Secondary outcome
measures include changes in body weight, fasting blood
glucose, blood pressure, quality of life and physical
activity.
Theoretical framework
The Health Belief Model (HBM) forms the basis for the
theoretical underpinning of this study [23]. HBM is a
conceptual framework that has been used extensively to
explain health behaviour [24]. However, the theoretical
HBM does not suggest a strategy for changing health-
related actions. Therefore, modifying factors which
include media, health professionals, personal relation-
ships, incentives and self-efficacy of recommended
health action create a “cue to action” for patients to
elicit behaviour compliance.
Articulation of study to HBM framework
Perceived barriers to self-care can hinder progress in
patient participation. Several perceived barriers deter
patient participation in regular SMBG. These include
inconvenient programme days and time, lack of feedback,
lack of reminders and the cost [25]. This study is designed
to address these common barriers. To make participation
convenient, follow-up sessions will be scheduled during
participants’ regular appointments at the clinics. To
address the barrier of time, diabetes classes will last for a
maximum of one hour, screening and follow-up consulta-
tions will take approximately 1 h, while focus group
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sessions will last up to 2 h, will be conducted at separate
sessions. Therefore, total contact time commitment for
the entire programme will be seven and a half hours over
a span of 1 year. To overcome the lack of feedback, partic-
ipants in the telemonitoring group will receive an auto-
mated e-mail reminder if self-monitoring of blood glucose
is not performed for three consecutive times while
monthly follow-up calls to participants in the control
group will be conducted. Furthermore, feedback will be
provided to participants if blood glucose results show
three continuous blood glucose values of ≤ 3.9 mmol/l or
≥11.1 mmol/l in the telemonitoring group. To overcome
the cost barrier, the programme will be offered free to all
participants.
Multidisciplinary committee
In order to enhance the community-specific intervention
of the study, a multidisciplinary committee will be estab-
lished to receive input from various experts including
doctors, pharmacists and nurses. The committee will
also provide assistance in participant enrolment, patient
counselling and disease education.
Phase 0–1: theoretical phase/modelling
The theoretical basis of this study was established by
reviewing published literature on the utilisation of
mobile technology in diabetes care [26–31]. To develop
a cultural-specific telemonitoring system that is suitable
for the Malaysian population, evidence of poor diabetes
management and its additional associated risks during
Ramadan was reviewed [32, 33]. This allowed for specifi-
cation of the required interventions that would
accommodate an ethnically diverse country like
Malaysia.
Phase 2: exploratory trial
This exploratory phase of the study focused on the use
of telemonitoring during the holy month of Ramadan.
During this period, Muslims are required to refrain from
consuming food and water from dawn till dusk. Studies
have shown that modified dietary habits could increase the
risk of severe hypoglycaemia by nearly 7.5-fold [33, 34].
Therefore, the objective of this exploratory phase was
to evaluate the effects of implementing a telemonitor-
ing programme to aid Muslims with type 2 diabetes
who were fasting during Ramadan. Ethics approval for
this study has been obtained from the Medical
Research and Ethics committee, Malaysia (NMRR-14-
177-19466) and Monash University Research Ethics
Committee (CF14/1977-2014001016).
Eligible participants included those who had been
diagnosed with type 2 diabetes, aged 18–75 years, with
HbA1c level between 7.5 and 11 %, willing to fast for
15 days, had internet access, an e-mail address and a
smartphone, and provided informed written consent.
Patients from five public health care centres were allo-
cated into usual care group (n = 19) or telemonitoring
group (n = 18) using clustered randomisation method.
Education materials which focused on diabetes manage-
ment during Ramadan were provided to participants to
standardise education level as well as diabetes manage-
ment practice.
During the 7-week intervention, a web-enabled glu-
cose meter (Entra Health System, San Diego, CA, USA),
Fig. 1 MRC framework adapted from Higginson et al. BMC Palliative Care 2006 5:7 [22]
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connected to an android phone, which could transmit re-
corded blood glucose results to a web portal, was provided
to all participants in the telemonitoring group. The device
also provided automatic feedback to the participant if his/
her recorded blood glucose results for three continuous
tests were ≤ 3.9 mmol/l or ≥11.1 mmol/l. A schematic dia-
gram representing the elements of this system is shown in
Fig. 2. Diaries were provided to all participants in the
study to record any hypoglycaemic events that occurred
during the study. Participants were encouraged to self-
monitor their blood glucose levels five times a day during
the month of Ramadan. Ten focus group sessions were
conducted to elicit participants’ experiences of fasting dur-
ing the month of Ramadan as well as the study design.
Results from the pilot study showed that hypoglycaemic
episodes were lower in the telemonitoring group com-
pared to the usual care group [35]. Focus group discussion
indicated that participants were open to new technologies,
which helped them in managing their disease. Several lim-
itations were noted during the exploratory phase of the
study. These were mostly related to the study design.
Since participants had to be recruited when they were
fasting during the month of Ramadan, this limited the
recruitment time and hence, the small sample size. In
addition, difficulty in accessing Internet connection
affected the delivery of the blood glucose results to the
researchers.
Randomised controlled trial (phase III)
The exploratory phase was conducted in a specific popu-
lation within a seasonal time period and generalisability
of the results could be limited. Generalisation to a larger
and more diverse population remains to be tested. To
overcome these limitations, we describe the design of a
larger study (IDEAS Study), which will take into consid-
erations the limitations noted in the pilot study.
Randomisation
The study will follow a cluster randomised design with
the public clinics as the unit of randomisation. This will
avoid potential contamination between individuals who
are assigned to different treatment groups in the same
study site. A trained individual, independent of the study
team will conduct all the randomisation.
Sample size calculation
A previous study in a tertiary hospital reported a 0.79 %
mean difference in HbA1c between adherent and
Patients will test their blood 
glucose levels from home. 
Results will be transmitted 
from glucometer to their 
phone.
HOME
Online 
platform
Patient’s data are 
automatically transmitted 
from phone to an online 
portal via a secure server
Secure 
Server 
Integration with EHR/PHR service 
providers
Web-based Clinician Access Portal
Patient Portal
Central Monitoring 
System
Data will be transmitted 
automatically onto the web 
portal to be viewed by 
researchers
Fig. 2 Technical schema of the proposed telemonitoring system
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non-adherent people with diabetes [36]. A sample size of
100 people per study arm will have an 80 % power to de-
tect a 0.5 % difference in HbA1c between the intervention
and control arm. Therefore, after accounting for a 20 %
loss to follow-up in each arm, 240 people with diabetes
will be recruited in this study.
Sample recruitment procedures
A range of recruitment strategies will be used to recruit
participants. Investigators will work closely with the doc-
tors as well as the nurses at the study sites to promote
and identify participants diagnosed with type 2 diabetes.
Participants may also be self-referred or referred through
their primary care doctors.
Selection criteria include people: (1) with type 2 dia-
betes based on diagnosis by a doctor, for at least
6 months prior to study enrolment, determined via self-
report with verification (medical records, current treat-
ment); (2) aged 18–75 years; (3) residing in the state of
Selangor without plans to leave for the next 12 months;
(4) with HbA1c levels of ≥ 7.5 % but less than 11.0 %
within the most recent 3 months; (5) who have regular
access to internet and an e-mail address or access to a
smartphone with 3G services. Participants will be ex-
cluded if they: (1) are unable or unwilling to give written
informed consent or communicate with local study staff;
(2) are currently diagnosed with mental disorder; (3)
have been hospitalised for depression in the past six
months; (4) do not have support from primary health-
care provider or family members; (5) are known to have
history of bariatric surgery, small bowel resection, or
extensive bowel resection, and (6) are currently pregnant
or breastfeeding.
Control arm
Participants in the control arm will be advised to con-
tinue their routine healthcare with their doctors, includ-
ing self-management of blood glucose and recording of
results in log books.
Intervention arm
Participants in this arm will be encourage to self-
monitor their blood glucose levels and will be provided
with a group-based diabetes education, an automated
feedback mechanism to both patient and family mem-
ber(s) as well as an electronic logbook. The web-enabled
function of the web-based glucose meter will be utilised,
which when connected to an android enabled smart-
phone device, will automatically upload any blood glu-
cose readings to an online portal which is currently
managed by the Entra Health System. The web portal
will host participant’s glycaemic and metabolic results as
well as other information such as self-management
skills, compliance to eye measurements and screening
for microvascular complications. The system will be cali-
brated to generate a message to inform the attending
doctor or researcher in the event that three consecutive
readings of hypoglycaemia (3.9 mmol/L or below) or
hyperglycaemia (11.1 mmol/L and above) are detected.
A schematic diagram representing the elements of this
system is shown in Fig. 2. The doctor or researcher will
have the option to use this information to initiate an
intervention. The doctor will be responsible for all treat-
ment decisions. Participants in the intervention arm will
receive monthly communications from the research
team. Communications will focus on self-management
skills, blood glucose control, and medication adherence.
Figure 3 shows the process of the study trial.
Focus group
To better understand participants’ perception towards
this research, focus group sessions will be conducted. In-
terested participants will be given an overview of the
purpose of the focus group discussion to ascertain their
interest in participating in this discussion. These sessions
will last between one and a half to two hours, and each
session will consist of not more than eight participants,
who will engage in discussion on the topics under con-
sideration. Selection of participants will be based on
common characteristics among them. A semi-structured
interview protocol using open-ended questions to
encourage group discussion, will be used and a trained
moderator will conduct the focus group sessions. The
moderator will provide nondirective, supportive and
non-evaluative role. He/she is also responsible to facili-
tate participants’ responses and to prevent deviation
from the topics being discussed. It is estimated that a
total of five focus groups will be required to achieve sat-
uration. Focus group sessions will be held at the times
convenient to the participants. Interviews with the vari-
ous healthcare professionals, including doctors and
nurses, will be conducted to understand their opinion
and acceptability in adapting telemonitoring into current
Malaysian healthcare settings.
Measurements
Table 1 details the measures that will be assessed
throughout the study. HbA1c will be analysed using ven-
ous samples by ion-exchange high performance liquid
chromatography (Cobas Integra 800, Roche), and serum
lipids using enzymatic techniques (Advia 2400, Siemens).
All blood specimens will be collected and analysed in a
central laboratory operated by Gribbles Pathology,
Malaysia to reduce variability.
Participants’ blood pressure will be calculated using
the mean of two measurements performed with partici-
pants seated after at least 10 min rest, with the cuff on
the predominant arm at the level of the heart (A&D,
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Table 1 Primary and secondary outcome measures for visit 0, 4, 12, 24, 52
Variable Instrument
Primary outcome variable
Glycaemic control HbA1c
Secondary outcome variable
Glycaemic control Fasting plasma glucose
Blood lipids Total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides
Kidney function Creatinine
Blood pressure Measured twice using A&D UA-767 Plus BT-C blood pressure device on the same arm.
Blood oxygen saturation and pulse rate Spo2; using Nonin Oximeter II Model 9560 on the right index finger.
Body Mass Index (BMI) Calculated from height and weight measured by research staff.
Self-efficacy Self-efficacy scale [46]
Diabetes distress Diabetes distress scale [37]
Diabetes self-care Diabetes self-care activities questionnaire [38]
Quality of life EQ-5D [40]
Healthcare utilization Self-reported using healthcare utilization questionnaire [39]
Smoking Self-reported
Co-morbidities Self-reported
LDL low density lipoprotein, HDL high density lipoprotein
Study Flow 
Analysed  (n= ?)
• Excluded from analysis (n=?) 
Analysed  (n= ? )
• Excluded from analysis (n=?)  
Analysis
Follow-up
• Assessment at month 1
• Assessment at month 3
• Assessment at month 6
• Assessment at month 12
Follow-up
• Assessment at month 1
• Assessment at month 3
• Assessment at month 6
• Assessment at month 12
Follow-Up
Assessed for eligibility 
Excluded (n=?)  
• Not meeting inclusion criteria
• Declined to participate 
• Other reasons
Allocated to intervention (n=120)
- Telemonitoring with group based 
education and automated feedback
Allocated to control (n=120)
- Routine health care with monthly 
telephone follow-up
Allocation
Randomise 11 clinics
(Total of 240 participants) 
Enrollment
Fig. 3 Schematic diagram of study trial process
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UA-767, USA). Body height and weight will be measured
in light indoor clothing and without shoes using a stadi-
ometer and a scale (A&D, UC-321 PBT-C, USA),
respectively. Blood oxygen saturation and pulse rate will
be measured using an oximeter (Nonin Oximeter II,
Model 9560, USA).
Several generic and disease-specific instruments will
be used in the current study to measure participants’
diabetes knowledge, quality of life, self-efficacy, diabetes
distress and health care utilization. These include the
diabetes distress scale [37], diabetes self-care activities
[38], health care utilization [39] and EuroQol-5D (EQ-5D)
[40]. Questionnaires will also be translated to Bahasa
Malaysia and Mandarin if required, and subsequently
validated.
Data analysis
Data quality
A unique study identifier will be used to tag all study
forms and biological samples which are collected during
this study. Quantitative data will be entered into a data-
base and audited for accuracy. In order to maintain par-
ticipant confidentiality, coded form will be kept
separately from the code list. Any missing and outlier
values will be screened by a research assistant and
hence, extensive training of research assistants is import-
ant to ensure quality of data entry.
Quantitative data analysis
Analysis of quantitative study data across randomised
groups will be conducted in IBM SPSS version 20
(Armonk, NY). Continuous variables will be tested for
normality and data, which are not normally distributed,
will be analysed using Kruskal-Wallis and Wilcoxon
signed ranks test. In the event of missing data, the last
observation carry forward method will be used. A p value
of < 0.05 will be considered as statistically significant for
all the tests.
Effectiveness of the research intervention will be mea-
sured in terms of differences between study arms with
respect to changes in biomedical measures and activities.
Logistic regression will be used and both adjusted and
unadjusted models will be presented. Benefits, barriers,
confidence and knowledge will be included in a model
to identify factors associated with the concept of inten-
sive treatment and hypoglycaemia. An adjusted t-test
using multiple linear regression analysis will be con-
ducted to calculate variables for benefits, barriers and
knowledge.
Qualitative data analysis
Focus group discussion will be transcribed verbatim and
qualitative responses will be independently reviewed by
the researchers (one psychologist, one pharmacist and
one research assistant) to identify themes and develop a
coding scheme.
Cost-effective analysis
We will conduct a literature review to identify studies,
which critically assessed the cost-effectiveness of an
intervention in diabetes in this region. We will also col-
lect data to examine healthcare resource use and indirect
costs using standard economic analytical tools. Cost ana-
lysis using direct and indirect costs will be performed on
the two study groups based on the number of referrals
to specialists (e.g. endocrinologists, optometrists, podia-
trist, dietitians), total clinic attendance and prescribed
medications and tests linked to diabetes. The indirect
costs will include travel cost, and cost such as days of
sick leave from work and premature early retirement
due to diabetes. The impact on quality of life will be
assessed using EQ-5D scale by interviewing patients
from the two groups before and after the intervention.
This data will be used to estimate the cost/Quality
Adjusted Life-Year (QALY) in cost utility analysis.
Discussion
The IDEAS study is designed to assess the feasibility,
effectiveness and cost effectiveness of a telemonitoring
programme for type 2 diabetes patients in primary care
settings. Previous studies have shown that telemonitor-
ing is effective to improve health behaviour and encour-
age self-management of chronic diseases [13, 41, 42].
However, the management of diabetes remains a com-
plex issue involving various aspects which include
behavioural, financial, and psychological factors. The
inclusion of various support structures especially from
family members and doctors have produced positive
results but further studies are required to incorporate
these findings into a real-life community setting in a
developing country, such as Malaysia [43–45].
This mix-method study that incorporates both quanti-
tative and qualitative methods will allow better under-
standing of the effectiveness as well as the receptiveness
of telemonitoring in a Malaysian community setting.
Additionally, insights from focus group discussion in this
study ensure that the intervention is relevant to a multi-
ethnic and culturally diverse country like Malaysia.
Therefore, this study will provide valuable information
in evaluating the effectiveness, acceptability and cost-
effectiveness of incorporating telemonitoring system in
managing diabetes in the Malaysian health care system.
Possible important limitations can be found in this
study. Due to the online nature of this study, results of
SMBG transmitted online may be delayed in areas with
limited internet access. Additionally, participants who
are less technology savvy will require more education in
using the new technology.
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Recruitment of participants commenced in April
2015, and data collection is scheduled to complete by
December 2016, after which final data analysis will be
performed and the findings will be presented in a
separate publication.
Relevance to public health
The results of this study will be of relevance to policy
makers on the importance of diabetes management
using telemonitoring. The 6-month follow-up period
will provide valuable data on the sustainability of the
effect of such programme over time. The findings of
this study will also enable better approaches to health
promotion and the management of chronic diseases
and their complications as well as serve as a source
of information on the success and limitations that
entailed in the implementation of a telemonitoring
programme.
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